eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

The crosstalk effect of cancer stem cells in the progression of pediatric medulloblastoma through signaling expression of CD133, CD44, and OCT4 with and without Wnt-b-catenin activation

Maher Kurdi
1
,
Alaa Alkhotani
2
,
Motaz Fadul
1
,
Huda Alghefari
1
,
Awab T. Tayyib
3
,
Thamer Alsharif
4
,
Majid Almansouri
5
,
Yazid Maghrabi
6
,
Shadi Alkhayyat
7
,
Taghreed Alsinani
8
,
Ahmed K. Bamaga
9
,
Saleh Baeesa
6

  1. Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
  2. Department of Pathology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
  3. Department of Pathology, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  4. Department of Surgery, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia
  5. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  6. Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
  7. Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  8. Department of Neurosurgery, King Fahad General Hospital, Jeddah, Saudi Arabia
  9. Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Folia Neuropathol 2024; 62 (4)
DOI: https://doi.org/10.5114/fn.2024.144903
Online publish date: 2024/11/20
Article file
- The crosstalk (2).pdf  [0.26 MB]
Get citation
 
PlumX metrics:
 
1. Annabi B, Doumit J, Plouffe K, Laflamme C, Lord-Dufour S, Béliveau R. Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133[+] DAOY medulloblastoma cells. Mol Carcinog 2010; 49: 710-717.
2. Azzarelli R, Simons BD, Philpott A. The developmental origin of brain tumours: a cellular and molecular framework. Development 2018; 145: dev162693.
3. Bahmad HF, Poppiti RJ. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. J Clin Pathol 2010; 73: 243-249.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
5. Bisson I, Prowse DM. Wnt signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009; 19: 683-697.
6. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007; 67: 1-5.
7. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Young Oh E, Gaber EW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
8. Cambruzzi E. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. Childs Nerv Syst 2018; 34: 809815.
9. Chang CJ, Chiang CH, Song WS, et al. Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nerv Syst 2012; 28: 363-373.
10. Cordeiro BM, Oliveira ID, Alves MT, Saba-Silva N, Capellano AM, Cavalheiro S, Dastoli P, Toledo SR. SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties. Childs Nerv Syst 2014; 30: 1165-1172.
11. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2017; 6: 1073-1085.
12. Da Silva PBG, Teixeira Dos Santos MC, Rodini CO, Kaid C, Pereira MCL, Furukawa G, Gimenes da Cruz DS, Goldfeder MB, Rocha CRR, Rosenberg C, Keith Okamoto O. High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells. Oncotarget 2017; 21: 19192-19204.
13. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007; 1: 241-242.
14. Dan Q, Wang F, Fonkem E, Jason H. Huang, Erxi Wu. CD44 as potential therapeutic target for medulloblastoma metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; Atlanta, GA. Philadelphia [PA]: AACR; Cancer Res 2019; 79[13 Suppl] nr 1122.
15. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2018; 10: 2821-2827.
16. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-7452.
17. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218: 86-94.
18. Frasson C, Rampazzo E, Accordi B, Beggio G, Pistollato F, Basso G, Persano L. Inhibition of PI3K signalling selectively affects medulloblastoma cancer stem cells. Biomed Res Int 2015; 2015: 1-11.
19. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 2004; 116: 769-778.
20. Glumac PM, LeBeau AM. The role of CD133 in cancer: a Concise review. Clin Transl Med 2018; 7: 18.
21. Gupta P, Rizvi SZ, Lal N, Gupta V, Srivastav AN, Musa O. Expression of CD44 and CD133 stem cell markers in squamous cell carcinoma of esophagus. Indian J Pathol Microbiol 2021; 64: 472-478.
22. Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G, Schindler C, Jones N, Klein-Franke A, Maier H, Jauk B, Kiefer A, Hainfellner JA. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 2006; 42: 2996-3003.
23. Hassan Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: A multifunctional mediator of cancer progression. Biomolecules 2021; 11: 1850.
24. Hatefi N, Nouraee N, Parvin M, Ziaee SAM, Mowla SJ. Evaluating the expression of oct4 as a prognostic tumor marker in bladder cancer. Iran J Basic Med Sci 2012; 15: 1154-1161.
25. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct “side population” of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-205.
26. Holmberg J, He X, Peredo I, Orrego A, Hesselager G, Ericsson C, Hovatta O, Oba-Shinjo SM, Marie SKN, Nistér M, Muhr J. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One 2011; 6: e18454.
27. Huang H, Wang C, Liu F, Li HZ, Peng G, Gao X, Dong KQ, Wang HR, Kong DP, Qu M, Dai LH, Wang KJ, Zhou Z, Yang J, Yang ZY, Cheng YQ, Tian QQ, Liu D, Xu CL, Xu DF, Cui XG, Sun YH. Reciprocal network between cancer stem-like cells and macrophages facilitates the progression and androgen deprivation therapy resistance of prostate cancer. Clin Cancer Res 2018; 24: 4612-4626.
28. Kim J, Choi KW, Lee J, Lee J, Lee S, Sun R, Kim J. Wnt/b-catenin signaling inhibitors suppress the tumor-initiating properties of a CD44+CD133+ subpopulation of Caco-2 cells. Int J Biol Sci 2021; 17: 1644-1659.
29. Kurdi M, Mulla N, Malibary H, Bamaga AK, Fadul MM, Faizo E, Hakamy S, Baeesa S. Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. World
30. J Clin Oncol 2023; 14: 117-130.
31. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin Ther Targets 2007; 11: 915-927.
32. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005; 8: 723-729.
33. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R,
34. von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23: 1231-1251.
35. Lu Y, Zhu H, Shan H, Lu J, Chang X, Li X, Lu J, Fan X, Zhu S, Wang Y,
36. Guo Q, Wang L, Huang Y, Zhu M, Wang Z. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett 2013; 340: 113-123.
37. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296.
38. Martin AM, Raabe E, Eberhart C, Cohen KJ. Management of pediatric and adult patients with medulloblastoma. Curr Treat Options Oncol 2014; 15: 581-594.
39. Moore MAS, Williams N, Metcalf D. In vitro colony formation by normal and leukemic human hematopoietic cells: characterization of the colony-forming cells 2. J Natl Cancer Inst 1973; 50: 603-623.
40. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-579.
41. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-391.
42. Okamoto K, Ninomiya I, Ohbatake Y, Hirose A, Tsukada T, Nakanuma S, Sakai S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Hidehiro T, Takamura H, Fushida S, Ohta T. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy. Oncol Rep 2016; 36: 3333-3342.
43. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 2018; 20: iv1-86.
44. Poursani EM, Mehravar M, Soltani BM, Mowla SJ. OCT4B2, a novel alternative spliced variant of OCT4, is significantly upregulated under heat-stress condition and downregulated in differentiated cells. Tumour Biol 2017; 101042831772428.
45. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov 2014; 13: 497-512.
46. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010; 28: 5188-5196.
47. Rodini CO, Suzuki DE, Saba-Silva N, Cappellano A, de Souza JES, Cavalheiro S, Toledo SRC, Okamoto OK. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neurooncol 2012; 106: 71-79.
48. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 2008; 14: 971-976.
49. Samardzija C, Luwor RB, Volchek M, Quinn MA, Findlay JK, Ahmed N. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. Mol Cancer 2015; 14: 152.
50. Saulnier O, Zagozewski J, Liang L, Hendrikse LD, Layug P, Gordon V, Aldinger KA, Haldipur P, Borlase S, Coudière-Morrison L, Cai T, Martell E, Gonzales NM, Palidwor G, Porter CJ, Richard S, Sharif T, Millen KJ, Doble BW, Taylor MD, Werbowetski-Ogilvie TE. A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing. Nat Cell Biol 2024; 26: 1233-1246.
51. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
52. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
53. Trosko JE. On the potential origin and characteristics of cancer stem cells. Carcinogenesis 2021; 42: 905-912.
54. Tsai SC, Chang DF, Hong C-M, Xia P, Senadheera D, Trump L, Mishra S, Lutzko C. Induced overexpression of OCT4A in human embryonic stem cells increases cloning efficiency. Am J Physiol Cell Physiol 2014; 306: C1108-1118.
55. Tsunekuni K, Konno M, Haraguchi N, Koseki J, Asai A, Matsuoka K, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H. CD44/CD133-positive colorectal cancer stem cells are sensitive to trifluridine exposure. Sci Rep 2019; 9: 14861.
56. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS, Bernstein ID. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 2000; 6: 1278-1281.
57. Wang X, Dai J. Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells 2010; 28: 885-893.
58. Yin X, Li YW, Jin JJ, Zhou Y, Ren ZG, Qiu SJ, Zhang BH. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett 2013; 5: 1155-1162.
59. Yokota N, Aruga J, Takai S, Yamada K, Hamazaki M, Iwase T, Sugimura H, Mikoshiba K. Predominant expression of human Zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 1996; 56: 377-383.
Copyright: © 2024 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Wprowadzenie do neurologopedii Wydanie II zaktualizowane
EVENTS
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.